Summit Therapeutics (SMMT) Q4 2024 Annual Earnings
SMMT·Reported February 24, 2025·Before market open
Diluted EPS came in at $-0.08, beat the $-0.08 consensus by $0.00.
Diluted EPS
$-0.08beat by $0.00
Consensus: $-0.08
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Summit Therapeutics's Q4 2024 earnings report.
Summit Therapeutics (SMMT) reported Q4 2024 earnings on February 24, 2025 before market open.
Summit Therapeutics reported diluted EPS of $-0.08 for Q4 2024.
EPS beat the consensus estimate of $-0.08 by $0.00.
You can read the 10-K periodic report (0001599298-25-000048) directly on SEC EDGAR. The filing index links above go to sec.gov.